临床淋巴结阴性腮腺恶性肿瘤中择区性颈淋巴结清扫的效用
基于美国国家癌症数据库(NCDB)的回顾性队列研究纳入9405例临床淋巴结阴性腮腺恶性肿瘤患者,其中3396例(36.1%)接受了择区性颈淋巴结清扫(END)。END最常用于鳞状细胞癌(SCC)和涎腺导管组织学;涎腺导管癌和腺癌的隐匿性淋巴结转移率最高(分别为39.8%和30.0%),其次为SCC(29.8%)。Kaplan-Meier分析显示,在接受END的低分化黏液表皮样癌患者以及中分化和低分化SCC患者中,5年总生存率有统计学显著提高。
要点
- 组织学分类是决定哪些患者应接受END的基准。
- 涎腺导管癌和腺癌的隐匿性淋巴结转移率最高(分别为39.8%和30.0%),其次为SCC(29.8%)。
- 低分化黏液表皮样癌及中、低分化SCC患者接受END后5年总生存率有统计学显著提高。
核心结论
- 组织学分类是决定哪些患者应接受END的基准。
- 接受END的低分化黏液表皮样癌和SCC患者总生存率提高。
- 组织学应与临床T分期和隐匿性淋巴结转移率一同考虑,以确定END的适用性。
研究设计与样本
- 回顾性队列数据库研究,使用美国国家癌症数据库(NCDB)。
- 纳入9405例临床淋巴结阴性腮腺恶性肿瘤患者,其中3396例(36.1%)接受了END。
- END定义为病理检查淋巴结数≥5枚,采用既往文献中的定义。
- 采用单因素和多因素分析比较接受END的预测因素、隐匿性转移率和生存。
主要发现
- END最常用于鳞状细胞癌(SCC)和涎腺导管组织学;与SCC相比,所有其他组织学类型接受END的可能性显著更低(p < .05)。
- 涎腺导管癌和腺癌的隐匿性淋巴结转移率最高(分别为39.8%和30.0%),其次为SCC(29.8%)。
- Kaplan-Meier生存分析显示,接受END的低分化黏液表皮样癌患者5年总生存率为56.2% vs 48.5%(p = .004)。
- 接受END的中分化SCC患者5年总生存率为43.2% vs 34.9%(p = .002),低分化SCC患者为48.9% vs 36.2%(p < .001)。
关键数值与推荐
- END定义为病理检查淋巴结数≥5枚。
- 涎腺导管癌隐匿性淋巴结转移率为39.8%,腺癌为30.0%,SCC为29.8%。
- 低分化黏液表皮样癌接受END的5年总生存率为56.2% vs 48.5%(p = .004)。
- 中分化SCC接受END的5年总生存率为43.2% vs 34.9%(p = .002),低分化SCC为48.9% vs 36.2%(p < .001)。
临床怎么用
- 组织学分类是决定哪些患者应接受END的基准。
- 组织学应与临床T分期和隐匿性淋巴结转移率一同考虑,以确定END的适用性。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We sought to investigate the utility of elective neck dissection (END) in clinically node-negative parotid malignancy through the evaluation of factors that are associated with receiving END and survival analysis of patients who received END. STUDY DESIGN: Retrospective cohort database study. SETTING: The National Cancer Database (NCDB). METHODS: The NCDB was used to extract patients with clinically node-negative parotid malignancy. END was defined as having 5 or more lymph nodes examined pathologically, as previously defined in the literature. Univariate and multivariate analyses were used to compare predictors of receiving END, rates of occult metastasis, and survival. RESULTS: Of the 9405 included patients, 3396 (36.1%) underwent an END. END was most frequently performed for squamous cell carcinoma (SCC) and salivary duct histology. All other histologies were significantly less likely to undergo END compared to SCC (p < .05). Salivary ductal carcinoma and adenocarcinoma had the greatest rates of occult node disease (39.8% and 30.0%, respectively), followed by SCC (29.8%). Kaplan-Meier survival analysis showed a statistically significant increase in 5-year overall survival in patients who received END with poorly differentiated mucoepidermoid (56.2% vs 48.5%, p = .004) along with moderately and poorly differentiated SCC (43.2% vs 34.9%, p = .002; 48.9% vs 36.2%, p < .001, respectively). CONCLUSION: Histological classification is a benchmark for determining which patients should receive an END. We demonstrated an increase in overall survival in patients who undergo END with poorly differentiated tumors of mucoepidermoid and SCC histology. As such, histology should be considered along with clinical T-stage and rate of occult nodal metastasis to determine eligibility for END.
引用
- Vedula S, Shah YS, Barinsky GL, et al. Utility of Elective Neck Dissection in Clinically Node-Negative Parotid Malignancy. Otolaryngol Head Neck Surg. 2023. PMID: 36807904. doi:10.1002/ohn.264
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。